Inflammatory stress exacerbates hepatic cholesterol accumulation via disrupting cellular cholesterol export

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 5, 2012, Pages 974-984

  Chen, Yuyang ^a   Chen, Yao ^a   Zhao, Lei ^a   Chen, Yaxi ^a   Mei, Mei ^a   Li, Qing ^a   Huang, Ailong ^a   Varghese, Zac ^b   Moorhead, John F ^b   Ruan, Xiong Z ^a,b  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Bile acid; Cholesterol efflux; Fatty liver; Inflammation; Liver x receptor

Indexed keywords

ABC TRANSPORTER A1; CASEIN; CHOLESTEROL 7ALPHA MONOOXYGENASE; INTERLEUKIN 6; LIVER X RECEPTOR ALPHA; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE ACID BLOOD LEVEL; BILE ACID SYNTHESIS; CELL STRAIN HEPG2; CHOLESTEROL LIVER LEVEL; CHOLESTEROL TRANSPORT; COLORIMETRY; CONTROLLED STUDY; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIPID DIET; LIPID STORAGE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCINTILLATION COUNTING; WESTERN BLOTTING;

EID: 84860243404     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06986.x     Document Type: Article

References (32)

1. Erickson SK. Nonalcoholic fatty liver disease. J. Lipid Res. 2009; 50 (Suppl.): S412-16.
2. Kallwitz ER, McLachlan A, Cotler SJ. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J. Gastroenterol. 2008; 14: 22-8.
3. Hardwick JP, Osei-Hyiaman D, Wiland H etal. PPAR/RXR regulation of fatty acid metabolism and fatty acid omega-Hydroxylase (CYP4) isozymes: implications for prevention of lipotoxicity in fatty liver disease. PPAR Res. 2009; 2009: 952734.
4. Fabbrini E, deHaseth D, Deivanayagam S etal. Alterations in fatty acid kinetics in obese adolescents with increased intrahepatic triglyceride content. Obesity (Silver Spring) 2009; 17: 25-9.
5. Caballero F, Fernandez A, De Lacy AM etal. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J. Hepatol. 2009; 50: 789-96.
6. Kainuma M, Fujimoto M, Sekiya N etal. Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J. Gastroenterol. 2006; 41: 971-80.
7. Zhang W, Kudo H, Kawai K etal. Tumor necrosis factor-alpha accelerates apoptosis of steatotic hepatocytes from a murine model of non-alcoholic fatty liver disease. Biochem. Biophys. Res. Commun. 2010; 391: 1731-6.
8. Senokuchi T, Liang CP, Seimon TA etal. Forkhead transcription factors (FoxOs) promote apoptosis of insulin-resistant macrophages during cholesterol-induced endoplasmic reticulum stress. Diabetes 2008; 57: 2967-76.
9. Wieckowska A, Zein NN, Yerian LM etal. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006; 44: 27-33.
10. Haukeland JW, Damas JK, Konopski Z etal. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. 2006; 44: 1167-74.
11. Lanza-Jacoby S, Phetteplace H, Sedkova N etal. Sequential alterations in tissue lipoprotein lipase, triglyceride secretion rates, and serum tumor necrosis factor alpha during Escherichia coli bacteremic sepsis in relation to the development of hypertriglyceridemia. Shock 1998; 9: 46-51.
12. Feingold KR, Soued M, Serio MK etal. Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinology 1989; 125: 267-74.
13. Kaneda M, Kashiwamura S, Ueda H etal. Inflammatory liver steatosis caused by IL-12 and IL-18. J. Interferon Cytokine Res. 2003; 23: 155-62.
14. Li Z, Yang S, Lin H etal. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-50.
15. Ma KL, Ruan XZ, Powis SH etal. Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. Hepatology 2008; 48: 770-81.
16. Zhao L, Chen Y, Tang R etal. Inflammatory stress exacerbates hepatic cholesterol accumulation via increasing cholesterol uptake and de novo synthesis. J. Gastroenterol. Hepatol. 2011; 26: 875-83.
17. Schwarz M, Russell DW, Dietschy JM etal. Marked reduction in bile acid synthesis in cholesterol 7alpha-hydroxylase-deficient mice does not lead to diminished tissue cholesterol turnover or to hypercholesterolemia. J. Lipid Res. 1998; 39: 1833-43.
18. Acuna-Alonzo V, Flores-Dorantes T, Kruit JK etal. A functional ABCA1 gene variant is associated with low HDL-cholesterol levels and shows evidence of positive selection in Native Americans. Hum. Mol. Genet. 2010; 19: 2877-85.
19. Tiemann M, Han Z, Soccio R etal. Cholesterol feeding of mice expressing cholesterol 7alpha-hydroxylase increases bile acid pool size despite decreased enzyme activity. Proc. Natl Acad. Sci. U.S.A. 2004; 101: 1846-51.
20. Shibata S, Hayakawa K, Egashira Y etal. Roles of nuclear receptors in the up-regulation of hepatic cholesterol 7alpha-hydroxylase by cholestyramine in rats. Life Sci. 2007; 80: 546-53.
21. Hunt MC, Yang YZ, Eggertsen G etal. The peroxisome proliferator-activated receptor alpha (PPARalpha) regulates bile acid biosynthesis. J. Biol. Chem. 2000; 275: 28947-53.
22. Russell DW. Nuclear orphan receptors control cholesterol catabolism. Cell 1999; 97: 539-42.
23. Chawla A, Boisvert WA, Lee CH etal. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell 2001; 7: 161-71.
24. Ruan XZ, Moorhead JF, Fernando R etal. PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J. Am. Soc. Nephrol. 2003; 14: 593-600.
25. Gamble W, Vaughan M, Kruth HS etal. Procedure for determination of free and total cholesterol in micro- or nanogram amounts suitable for studies with cultured cells. J. Lipid Res. 1978; 19: 1068-70.
26. Mroszczak EJ, Riegelman S. Rapid spectrofluorometric assay for total bile salts in bile. Clin. Chem. 1972; 18: 987-91.
27. Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am. J. Gastroenterol. 2008; 103: 1036-42.
28. Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol. Metab. 2008; 19: 371-9.
29. Wittenburg H, Carey MC. Biliary cholesterol secretion by the twinned sterol half-transporters ABCG5 and ABCG8. J. Clin. Invest. 2002; 110: 605-9.
30. Gelissen IC, Harris M, Rye KA etal. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler. Thromb. Vasc. Biol. 2006; 26: 534-40.
31. Timmins JM, Lee JY, Boudyguina E etal. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J. Clin. Invest. 2005; 115: 1333-42.
32. Ide T, Shimano H, Yoshikawa T etal. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. Mol. Endocrinol. 2003; 17: 1255-67.